Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease

Cancer Cell

Volumn 27, Issue 1, 2015, Pages 72-84

  Hill, Rebecca M ^a   Kuijper, Sanne ^b   Lindsey, Janet C ^a   Petrie, Kevin ^b   Schwalbe, Ed C ^a   Barker, Karen ^b   Boult, Jessica K R ^b   Williamson, Daniel ^a   Ahmad, Zai ^b   Hallsworth, Albert ^b   Ryan, Sarra L ^a   Poon, Evon ^b   Robinson, Simon P ^b   Ruddle, Ruth ^b   Raynaud, Florence I ^b   Howell, Louise ^b   Kwok, Colin ^b   Joshi, Abhijit ^c   Nicholson, Sarah Leigh ^a   Crosier, Stephen ^a   Ellison, David W ^d   Wharton, Stephen B ^e   Robson, Keith ^f   Michalski, Antony ^g   Hargrave, Darren ^g   Jacques, Thomas S ^g,h   Pizer, Barry ⁱ   Bailey, Simon ^a   Swartling, Fredrik J ^j   Weiss, W A ^k,l,m   Chesler, Louis ^b   Clifford, Steven C ^a   more..

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c ROYAL VICTORIA INFIRMARY   (United Kingdom)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^e UNIVERSITY OF SHEFFIELD   (United Kingdom)

^f UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^g GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^h UNIVERSITY COLLEGE LONDON   (United Kingdom)

ⁱ ALDER HEY CHILDREN S HOSPITAL   (United Kingdom)

^j UPPSALA UNIVERSITY   (Sweden)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MYC PROTEIN; PROTEIN P53; ANTINEOPLASTIC AGENT; MYC PROTEIN, HUMAN; MYCN PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; TP53 PROTEIN, HUMAN;

ARTICLE; CLINICAL ARTICLE; COPY NUMBER VARIATION; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MEDULLOBLASTOMA; MOLECULAR PATHOLOGY; ONCOGENE MYC; PRIORITY JOURNAL; PROTEIN DEFECT; PROTEIN PROTEIN INTERACTION; TRANSGENIC ORGANISM; TUMOR BIOPSY; TUMOR GROWTH; TUMOR RECURRENCE; ADOLESCENT; ADULT; ANIMAL; CEREBELLAR NEOPLASMS; CHILD; EXPERIMENTAL NEOPLASM; FEMALE; GENETICS; INFANT; MALE; METABOLISM; MOLECULAR GENETICS; MOUSE; MUTATION; PATHOLOGY; PRESCHOOL CHILD; SIGNAL TRANSDUCTION; YOUNG ADULT;

ADOLESCENT; ADULT; ANIMALS; ANTINEOPLASTIC AGENTS; CEREBELLAR NEOPLASMS; CHILD; CHILD, PRESCHOOL; FEMALE; GENE AMPLIFICATION; HUMANS; INFANT; MALE; MEDULLOBLASTOMA; MICE; MOLECULAR SEQUENCE DATA; MUTATION; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, EXPERIMENTAL; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MYC; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 84922235074     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2014.11.002     Document Type: Article

References (48)

1. Abdi, H. (2007). Bonferroni and Sidak corrections for multiple comparisons. In Encyclopedia of Measurement and Statistics, N.J. Salkind, ed. (Thousand Oaks, CA: Sage).
2. Berggren, P., Kumar, R., Sakano, S., Hemminki, L., Wada, T., Steineck, G., Adolfsson, J., Larsson, P., Norming, U., Wijkstrom, H., and Hemminki, K. (2003). Detecting homozygous deletions in the CDKN2A(p16(INK4a))/ ARF(p14(ARF)) gene in urinary bladder cancer using real-time quantitative PCR. Clin. Cancer Res. 9, 235-242.
3. Brockmann, M., Poon, E., Berry, T., Carstensen, A., Deubzer, H.E., Rycak, L., Jamin, Y., Thway, K., Robinson, S.P., Roels, F., et al. (2013). Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma. Cancer Cell 24, 75-89.
4. Carol, H., Reynolds, C.P., Kang, M.H., Keir, S.T., Maris, J.M., Gorlick, R., Kolb, E.A., Billups, C.A., Geier, B., Kurmasheva, R.T., et al. (2013). Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program. Pediatr. Blood Cancer 60, 633-641.
5. Carr-Wilkinson, J., O'Toole, K., Wood, K.M., Challen, C.C., Baker, A.G., Board, J.R., Evans, L., Cole, M., Cheung, N.K., Boos, J., et al. (2010). High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma. Clin. Cancer Res. 16, 1108-1118.
6. Chang, C.H., Housepian, E.M., and Herbert, C., Jr. (1969). An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas. Radiology 93, 1351-1359.
7. Chène, P. (2003). Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat. Rev. Cancer 3, 102-109.
8. Chesler, L., Schlieve, C., Goldenberg, D.D., Kenney, A., Kim, G., McMillan, A., Matthay, K.K., Rowitch, D., and Weiss, W.A. (2006). Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma. Cancer Res. 66, 8139-8146.
9. Christophorou, M.A., Martin-Zanca, D., Soucek, L., Lawlor, E.R., Brown- Swigart, L., Verschuren, E.W., and Evan, G.I. (2005). Temporal dissection of p53 function in vitro and in vivo. Nat. Genet. 37, 718-726.
10. Ellison, D.W., Onilude, O.E., Lindsey, J.C., Lusher, M.E., Weston, C.L., Taylor, R.E., Pearson, A.D., and Clifford, S.C. (2005). beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee. J. Clin. Oncol. 23, 7951-7957.
11. Ellison, D.W., Kocak, M., Dalton, J., Megahed, H., Lusher, M.E., Ryan, S.L., Zhao, W., Nicholson, S.L., Taylor, R.E., Bailey, S., and Clifford, S.C. (2011). Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. J. Clin. Oncol. 29, 1400-1407.
12. Frank, A.J., Hernan, R., Hollander, A., Lindsey, J.C., Lusher, M.E., Fuller, C.E., Clifford, S.C., and Gilbertson, R.J. (2004). The TP53-ARF tumor suppressor pathway is frequently disrupted in large/cell anaplastic medulloblastoma. Brain Res. Mol. Brain Res. 121, 137-140.
13. Gustafson, W.C., Meyerowitz, J.G., Nekritz, E.A., Chen, J., Benes, C., Charron, E., Simonds, E.F., Seeger, R., Matthay, K.K., Hertz, N.T., et al. (2014). Drugging MYCN through an allosteric transition in Aurora kinase A. Cancer Cell 26, 414-427.
14. Hovestadt, V., Remke, M., Kool, M., Pietsch, T., Northcott, P.A., Fischer, R., Cavalli, F.M., Ramaswamy, V., Zapatka, M., Reifenberger, G., et al. (2013). Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays. Acta Neuropathol. 125, 913-916.
15. Jones, D.T., Jäger, N., Kool, M., Zichner, T., Hutter, B., Sultan, M., Cho, Y.J., Pugh, T.J., Hovestadt, V., Stütz, A.M., et al. (2012). Dissecting the genomic complexity underlying medulloblastoma. Nature 488, 100-105.
16. Kawauchi, D., Robinson, G., Uziel, T., Gibson, P., Rehg, J., Gao, C., Finkelstein, D., Qu, C., Pounds, S., Ellison, D.W., et al. (2012). A mouse model of the most aggressive subgroup of human medulloblastoma. Cancer Cell 21, 168-180.
17. Kool, M., Korshunov, A., Remke, M., Jones, D.T., Schlanstein, M., Northcott, P.A., Cho, Y.J., Koster, J., Schouten-van Meeteren, A., van Vuurden, D., et al. (2012). Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol. 123, 473-484.
18. Lamont, J.M., McManamy, C.S., Pearson, A.D., Clifford, S.C., and Ellison, D.W. (2004). Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients. Clin. Cancer Res. 10, 5482-5493.
19. Langdon, J.A., Lamont, J.M., Scott, D.K., Dyer, S., Prebble, E., Bown, N., Grundy, R.G., Ellison, D.W., and Clifford, S.C. (2006). Combined genomewide allelotyping and copy number analysis identify frequent genetic losses without copy number reduction in medulloblastoma. Genes Chromosomes Cancer 45, 47-60.
20. Lannering, B., Rutkowski, S., Doz, F., Pizer, B., Gustafsson, G., Navajas, A., Massimino, M., Reddingius, R., Benesch, M., Carrie, C., et al. (2012). Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial. J. Clin. Oncol. 30, 3187-3193.
21. Louis, D.N., Ohgaki, H., Wiestler, O.D., Cavenee, W.K., Burger, P.C., Jouvet, A., Scheithauer, B.W., and Kleihues, P. (2007). The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114, 97-109.
22. McManamy, C.S., Pears, J., Weston, C.L., Hanzely, Z., Ironside, J.W., Taylor, R.E., Grundy, R.G., Clifford, S.C., and Ellison, D.W. (2007). Nodule formation and desmoplasia in medulloblastomas-defining the nodular/desmoplastic variant and its biological behavior. Brain Pathol. 17, 151-164.
23. Nicholson, J., Wickramasinghe, C., Ross, F., Crolla, J., and Ellison, D. (2000). Imbalances of chromosome 17 in medulloblastomas determined by comparative genomic hybridisation and fluorescence in situ hybridisation. Mol. Pathol. 53, 313-319.
24. Northcott, P.A., Jones, D.T., Kool, M., Robinson, G.W., Gilbertson, R.J., Cho, Y.J., Pomeroy, S.L., Korshunov, A., Lichter, P., Taylor, M.D., and Pfister, S.M. (2012a). Medulloblastomics: the end of the beginning. Nat. Rev. Cancer 12, 818-834.
25. Northcott, P.A., Shih, D.J., Peacock, J., Garzia, L., Morrissy, A.S., Zichner, T., Stütz, A.M., Korshunov, A., Reimand, J., Schumacher, S.E., et al. (2012b). Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature 488, 49-56.
26. Pei, Y., Moore, C.E., Wang, J., Tewari, A.K., Eroshkin, A., Cho, Y.J., Witt, H., Korshunov, A., Read, T.A., Sun, J.L., et al. (2012). An animal model of MYCdriven medulloblastoma. Cancer Cell 21, 155-167.
27. Pfaff, E., Remke, M., Sturm, D., Benner, A., Witt, H., Milde, T., von Bueren, A.O., Wittmann, A., Schöttler, A., Jorch, N., et al. (2010). TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma. J. Clin. Oncol. 28, 5188-5196.
28. Pfister, S., Remke, M., Benner, A., Mendrzyk, F., Toedt, G., Felsberg, J., Wittmann, A., Devens, F., Gerber, N.U., Joos, S., et al. (2009). Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J. Clin. Oncol. 27, 1627-1636.
29. Pizer, B.L., and Clifford, S.C. (2009). The potential impact of tumour biology on improved clinical practice for medulloblastoma: progress towards biologically driven clinical trials. Br. J. Neurosurg. 23, 364-375.
30. Pizer, B., Donachie, P.H., Robinson, K., Taylor, R.E., Michalski, A., Punt, J., Ellison, D.W., and Picton, S. (2011). Treatment of recurrent central nervous system primitive neuroectodermal tumours in children and adolescents: results of a Children's Cancer and Leukaemia Group study. Eur. J. Cancer 47, 1389-1397.
31. Ramaswamy, V., Remke, M., Bouffet, E., Faria, C.C., Perreault, S., Cho, Y.J., Shih, D.J., Luu, B., Dubuc, A.M., Northcott, P.A., et al. (2013). Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. Lancet Oncol. 14, 1200-1207.
32. Randerson-Moor, J.A., Harland, M., Williams, S., Cuthbert-Heavens, D., Sheridan, E., Aveyard, J., Sibley, K., Whitaker, L., Knowles, M., Bishop, J.N., and Bishop, D.T. (2001). A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family. Hum. Mol. Genet. 10, 55-62.
33. Robinson, G., Parker, M., Kranenburg, T.A., Lu, C., Chen, X., Ding, L., Phoenix, T.N., Hedlund, E., Wei, L., Zhu, X., et al. (2012). Novel mutations target distinct subgroups of medulloblastoma. Nature 488, 43-48.
34. Rudin, C.M., Hann, C.L., Laterra, J., Yauch, R.L., Callahan, C.A., Fu, L., Holcomb, T., Stinson, J., Gould, S.E., Coleman, B., et al. (2009). Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N. Engl. J. Med. 361, 1173-1178.
35. Rutkowski, S., Gerber, N.U., von Hoff, K., Gnekow, A., Bode, U., Graf, N., Berthold, F., Henze, G., Wolff, J.E., Warmuth-Metz, M., et al. (2009). Treatment of early childhood medulloblastoma by postoperative chemotherapy and deferred radiotherapy. Neuro-oncol. 11, 201-210.
36. Ryan, S.L., Schwalbe, E.C., Cole, M., Lu, Y., Lusher, M.E., Megahed, H., O'Toole, K., Nicholson, S.L., Bognar, L., Garami, M., et al. (2012). MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma. Acta Neuropathol. 123, 501-513.
37. Schwalbe, E.C., Williamson, D., Lindsey, J.C., Hamilton, D., Ryan, S.L., Megahed, H., Garami, M., Hauser, P., Dembowska-Baginska, B., Perek, D., et al. (2013). DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies. Acta Neuropathol. 125, 359-371.
38. Shakhova, O., Leung, C., van Montfort, E., Berns, A., and Marino, S. (2006). Lack of Rb and p53 delays cerebellar development and predisposes to large cell anaplastic medulloblastoma through amplification of N-Myc and Ptch2. Cancer Res. 66, 5190-5200.
39. Shih, D.J., Northcott, P.A., Remke, M., Korshunov, A., Ramaswamy, V., Kool, M., Luu, B., Yao, Y., Wang, X., Dubuc, A.M., et al. (2014). Cytogenetic prognostication within medulloblastoma subgroups. J. Clin. Oncol. 32, 886-896.
40. Sturm, D., Witt, H., Hovestadt, V., Khuong-Quang, D.A., Jones, D.T., Konermann, C., Pfaff, E., Tönjes, M., Sill, M., Bender, S., et al. (2012). Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22, 425-437.
41. Swartling, F.J., Grimmer, M.R., Hackett, C.S., Northcott, P.A., Fan, Q.W., Goldenberg, D.D., Lau, J., Masic, S., Nguyen, K., Yakovenko, S., et al. (2010). Pleiotropic role for MYCN in medulloblastoma. Genes Dev. 24, 1059-1072.
42. Tabori, U., Baskin, B., Shago, M., Alon, N., Taylor, M.D., Ray, P.N., Bouffet, E., Malkin, D., and Hawkins, C. (2010). Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations. J. Clin. Oncol. 28, 1345-1350.
43. Taketo, M., Schroeder, A.C., Mobraaten, L.E., Gunning, K.B., Hanten, G., Fox, R.R., Roderick, T.H., Stewart, C.L., Lilly, F., Hansen, C.T., et al. (1991). FVB/N: an inbred mouse strain preferable for transgenic analyses. Proc. Natl. Acad. Sci. USA 88, 2065-2069.
44. Tamayo, P., Scanfeld, D., Ebert, B.L., Gillette, M.A., Roberts, C.W., and Mesirov, J.P. (2007). Metagene projection for cross-platform, cross-species characterization of global transcriptional states. Proc. Natl. Acad. Sci. USA 104, 5959-5964.
45. Taylor, M.D., Northcott, P.A., Korshunov, A., Remke, M., Cho, Y.J., Clifford, S.C., Eberhart, C.G., Parsons, D.W., Rutkowski, S., Gajjar, A., et al. (2012). Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol. 123, 465-472.
46. Van Maerken, T., Rihani, A., Van Goethem, A., De Paepe, A., Speleman, F., and Vandesompele, J. (2014). Pharmacologic activation of wild-type p53 by nutlin therapy in childhood cancer. Cancer Lett. 344, 157-165.
47. Workman, P., Aboagye, E.O., Balkwill, F., Balmain, A., Bruder, G., Chaplin, D.J., Double, J.A., Everitt, J., Farningham, D.A.H., Glennie, M.J., et al.; Committee of the National Cancer Research Institute (2010). Guidelines for the welfare and use of animals in cancer research. Br. J. Cancer 102, 1555-1577.
48. Zhukova, N., Ramaswamy, V., Remke, M., Pfaff, E., Shih, D.J., Martin, D.C., Castelo-Branco, P., Baskin, B., Ray, P.N., Bouffet, E., et al. (2013). Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J. Clin. Oncol. 31, 2927-2935.